Albert Martínez-Pinteño
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Albert Martínez-Pinteño has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Patricia Gassó
Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
12 shared publications - Natalia Rodríguez
Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
11 shared publications - David Olivares-Berjaga
Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
8 shared publications - Sergi Mas
Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
8 shared publications - Eduard Parellada
Barcelona Clínic Schizophrenia Unit (BCSU), Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain
7 shared publications - Constanza Morén
Fundamental and Clinical Nursing Department, Faculty of Nursing University of Barcelona, Health Sciences Campus Bellvitge, Hospitalet de Llobregat Barcelona Spain
6 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (13) , 1987
Body Image Disturbance and Body Dissatisfaction in Sisters of Adolescent Girls with Anorexia Nervosa: A Narrative Review and a Preliminary Study
Background: Body image disturbance (BID) involves a distorted perception of one’s body, whereas body dissatisfaction (BDS) reflects negative affective evaluation of body appearance. Both are central features of eating disorders such as anorexia nervosa (AN), but their expression in siblings of affected individuals remains underexplored, particularly in younger populations. Methods: This cross-sectional preliminary study included 53 full sisters of adolescent patients with severe AN treated in a tertiary hospital. Participants underwent anthropometric assessment and completed standardized measures of BID, BDS, physical activity, eating-related attitudes, perfectionism, anxiety, and depressive symptoms. Results: Participants exhibited marked body size overestimation (mean relative BID = +45.2%), with 64.2% classified as high overestimators and 3.8% as underestimators. Overestimation was most pronounced in the waist, chest, and calves. BID was not significantly associated with BDS or with anthropometric measures, including body mass index. BDS showed significant positive correlations with depressive symptoms and self-oriented perfectionism, whereas BID was positively associated with physical activity. No significant associations were found between BID or BDS and age, socioeconomic status, or birth order. Conclusions: Sisters of adolescents with severe AN show substantial perceptual distortion of body size without corresponding levels of body dissatisfaction, suggesting partial independence between perceptual and affective components of body image. These findings identify a potentially vulnerable group and highlight the need for longitudinal studies to clarify mechanisms and inform preventive strategies.
- 3 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (13) , 1987
Open AccessBody Image Disturbance and Body Dissatisfaction in Sisters of Adolescent Girls with Anorexia Nervosa: A Narrative Review and a Preliminary Study
Background: Body image disturbance (BID) involves a distorted perception of one’s body, whereas body dissatisfaction (BDS) reflects negative affective evaluation of body appearance. Both are central features of eating disorders such as anorexia nervosa (AN), but their expression in siblings of affected individuals remains underexplored, particularly in younger populations. Methods: This cross-sectional preliminary study included 53 full sisters of adolescent patients with severe AN treated in a tertiary hospital. Participants underwent anthropometric assessment and completed standardized measures of BID, BDS, physical activity, eating-related attitudes, perfectionism, anxiety, and depressive symptoms. Results: Participants exhibited marked body size overestimation (mean relative BID = +45.2%), with 64.2% classified as high overestimators and 3.8% as underestimators. Overestimation was most pronounced in the waist, chest, and calves. BID was not significantly associated with BDS or with anthropometric measures, including body mass index. BDS showed significant positive correlations with depressive symptoms and self-oriented perfectionism, whereas BID was positively associated with physical activity. No significant associations were found between BID or BDS and age, socioeconomic status, or birth order. Conclusions: Sisters of adolescents with severe AN show substantial perceptual distortion of body size without corresponding levels of body dissatisfaction, suggesting partial independence between perceptual and affective components of body image. These findings identify a potentially vulnerable group and highlight the need for longitudinal studies to clarify mechanisms and inform preventive strategies.
- Open Access
- 26 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1772
Psychopathology and Other Mental Health Challenges in Siblings of Patients with Child- or Adolescent-Onset Anorexia Nervosa: A Systematic Review with a Sex/Gender Perspective
Background/Objectives: Anorexia nervosa (AN) is a severe psychiatric-metabolic disorder with high morbidity and mortality, profoundly impacting family systems. Siblings of patients with AN constitute a vulnerable group, yet there is a lack of specific, quantitative evidence on their mental health status, particularly when examined from a sex/gender perspective. This review aimed to synthesize existing evidence on the prevalence of psychiatric symptoms, diagnoses, and other mental health challenges in siblings of individuals with AN and critically analyze it from a sex/gender perspective. Methods: Following PRISMAguidelines, a systematic search was conducted across five databases (April–May 2025). The protocol was registered in PROSPERO (CRD420251025535). Sixteen studies published between 1983 and 2022 met eligibility criteria. Results: Included studies were rated as high or moderate quality, and overall risk of bias was estimated as low–moderate. Only half of the studies included brothers, and overall quality assessment from a sex/gender perspective was modest. Dimensional psychopathology assessments found increased prevalence of both internalizing and externalizing symptoms in siblings compared to controls, although siblings were generally more like controls than affected probands in psychometric evaluations. The few studies based on clinically diagnosed psychopathology state that siblings are at increased risk of several mental health disorders. Conclusions: Specific quantitative evidence on psychiatric diagnoses, psychopathology and other mental health challenges in siblings of individuals with AN is relatively scarce and biased, particularly by systematic exclusion of externalizing symptoms and male siblings. Future translational research should be designed and interpreted using a sex/gender perspective and prioritize systematic assessment by clinicians.
- 26 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1772
Open AccessPsychopathology and Other Mental Health Challenges in Siblings of Patients with Child- or Adolescent-Onset Anorexia Nervosa: A Systematic Review with a Sex/Gender Perspective
Background/Objectives: Anorexia nervosa (AN) is a severe psychiatric-metabolic disorder with high morbidity and mortality, profoundly impacting family systems. Siblings of patients with AN constitute a vulnerable group, yet there is a lack of specific, quantitative evidence on their mental health status, particularly when examined from a sex/gender perspective. This review aimed to synthesize existing evidence on the prevalence of psychiatric symptoms, diagnoses, and other mental health challenges in siblings of individuals with AN and critically analyze it from a sex/gender perspective. Methods: Following PRISMAguidelines, a systematic search was conducted across five databases (April–May 2025). The protocol was registered in PROSPERO (CRD420251025535). Sixteen studies published between 1983 and 2022 met eligibility criteria. Results: Included studies were rated as high or moderate quality, and overall risk of bias was estimated as low–moderate. Only half of the studies included brothers, and overall quality assessment from a sex/gender perspective was modest. Dimensional psychopathology assessments found increased prevalence of both internalizing and externalizing symptoms in siblings compared to controls, although siblings were generally more like controls than affected probands in psychometric evaluations. The few studies based on clinically diagnosed psychopathology state that siblings are at increased risk of several mental health disorders. Conclusions: Specific quantitative evidence on psychiatric diagnoses, psychopathology and other mental health challenges in siblings of individuals with AN is relatively scarce and biased, particularly by systematic exclusion of externalizing symptoms and male siblings. Future translational research should be designed and interpreted using a sex/gender perspective and prioritize systematic assessment by clinicians.
- Open Access
- 31 October 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-7
Association of astrocyte-specific gene expression in the dorsolateral prefrontal cortex with clozapine treatment in schizophrenia
Gene expression profiling studies could be a valuable tool in identifying the specific genes and pathways involved in the mechanism of action of clozapine, leading to a better understanding of the molecular biology underlying treatment-resistant schizophrenia (TRS). We aimed to identify the co-expressed modules that reflect the genetic differences between clozapine-treated and non-clozapine-treated patients with schizophrenia as a proxy of TRS. Gene expression of DLPFC samples from 26 subjects with schizophrenia (13 clozapine treated and 13 non-clozapine treated) were analyzed using Clariom S Human Array. Weighted gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its association with clozapine treatment. As a result of our analysis of the gene co-expression architecture in the DLPFC, among the 13 modules identified, one module (green) was significantly associated with clozapine treatment (p = 3.7 × 10−2). This module was significantly enriched in astrocyte markers (5.7 × 10−29) and genes involved in the polygenic architecture of TRS (1.6 × 10−2). This finding provides cell type-specific associations that could help in the interpretation of the neurobiological basis of TRS. A better understanding of the specific DLPFC cell types involved in clozapine treatment will contribute to the study of potential pathways and ultimately help improve psychiatric classification tools in personalized medicine.
- 31 October 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-7
Open AccessAssociation of astrocyte-specific gene expression in the dorsolateral prefrontal cortex with clozapine treatment in schizophrenia
Gene expression profiling studies could be a valuable tool in identifying the specific genes and pathways involved in the mechanism of action of clozapine, leading to a better understanding of the molecular biology underlying treatment-resistant schizophrenia (TRS). We aimed to identify the co-expressed modules that reflect the genetic differences between clozapine-treated and non-clozapine-treated patients with schizophrenia as a proxy of TRS. Gene expression of DLPFC samples from 26 subjects with schizophrenia (13 clozapine treated and 13 non-clozapine treated) were analyzed using Clariom S Human Array. Weighted gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its association with clozapine treatment. As a result of our analysis of the gene co-expression architecture in the DLPFC, among the 13 modules identified, one module (green) was significantly associated with clozapine treatment (p = 3.7 × 10−2). This module was significantly enriched in astrocyte markers (5.7 × 10−29) and genes involved in the polygenic architecture of TRS (1.6 × 10−2). This finding provides cell type-specific associations that could help in the interpretation of the neurobiological basis of TRS. A better understanding of the specific DLPFC cell types involved in clozapine treatment will contribute to the study of potential pathways and ultimately help improve psychiatric classification tools in personalized medicine.
- Open Access
- 11 October 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 192, 118639
Effects of JNJ-46356479 and clozapine on VGLUT1 and GAD65/67 brain levels and expression of genes related to glutamate and GABA in mice postnatally exposed to ketamine
- 11 October 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 192, 118639
Open AccessEffects of JNJ-46356479 and clozapine on VGLUT1 and GAD65/67 brain levels and expression of genes related to glutamate and GABA in mice postnatally exposed to ketamine
- Open Access
- 7 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8718
The Potential of Hair Matrix for Biomarker Analysis in Schizophrenia
Schizophrenia (SCZ) is a complex psychiatric disorder with positive, negative, and cognitive symptoms that cause long-term functional impairment. Despite available treatments, limitations in addressing cognitive and negative symptoms, medication side effects, and poor adherence highlight the need for novel biomarkers to support precision medicine. Hair has emerged as a promising, non-invasive biological matrix for biomarker research. Hair analysis has been explored to detect trace elements, abused drugs, antipsychotics, cortisol, neurotransmitters, and to assess gene expression, with results often consistent with blood, urine, and post-mortem tissues. Its advantages include ease of sampling and the ability to provide long-term information, while limitations involve individual variability and methodological inconsistencies. This review summarizes current evidence on hair-based biomarkers in SCZ, critically evaluating their potential and challenges. By integrating molecular, metabolic, and genetic findings, we highlight the value of hair as a complementary tool for advancing biomarker discovery and personalized approaches in SCZ.
- 7 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8718
Open AccessThe Potential of Hair Matrix for Biomarker Analysis in Schizophrenia
Schizophrenia (SCZ) is a complex psychiatric disorder with positive, negative, and cognitive symptoms that cause long-term functional impairment. Despite available treatments, limitations in addressing cognitive and negative symptoms, medication side effects, and poor adherence highlight the need for novel biomarkers to support precision medicine. Hair has emerged as a promising, non-invasive biological matrix for biomarker research. Hair analysis has been explored to detect trace elements, abused drugs, antipsychotics, cortisol, neurotransmitters, and to assess gene expression, with results often consistent with blood, urine, and post-mortem tissues. Its advantages include ease of sampling and the ability to provide long-term information, while limitations involve individual variability and methodological inconsistencies. This review summarizes current evidence on hair-based biomarkers in SCZ, critically evaluating their potential and challenges. By integrating molecular, metabolic, and genetic findings, we highlight the value of hair as a complementary tool for advancing biomarker discovery and personalized approaches in SCZ.
- Top Cited PapersOpen Access
- 6 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4415
Mitochondrial Oxidative Phosphorylation System Dysfunction in Schizophrenia
Schizophrenia (SCZ) is a severe, chronic mental disorder of unknown etiology and limited therapeutic options. Bioenergetic deficits in the oxidative phosphorylation system (OXPHOS) during early postnatal brain development may underlie disrupted neuronal metabolism and synaptic signaling, contributing to the neurodevelopmental and behavioral disturbances observed in patients. This narrative review summarizes updated evidence linking mitochondrial-OXPHOS dysfunction to SCZ pathophysiology. The novelty lies in the focus on OXPHOS dysfunction at the enzymatic/functional level, rather than on genetic, transcriptional, or oxidative parameters. While complex I impairment has long been highlighted and proposed as a peripheral marker of the disease, recent studies also report alterations in other OXPHOS complexes and their precursors. These findings suggest that OXPHOS dysfunction is not isolated to a single enzymatic component but affects broader mitochondrial function, alongside oxidative stress, contributing to disease progression through mechanisms involving apoptosis, accelerated aging, and synaptic deterioration. OXPHOS dysfunction in both central and peripheral tissues further supports its relevance to SCZ. Overall, the literature points to mitochondrial OXPHOS abnormalities as a significant biological feature of SCZ. Whether these alterations are causal factors or consequences of disease processes remains unclear. Understanding OXPHOS dysregulation may open new avenues for targeted therapies.
- 6 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4415
Top Cited PapersOpen AccessMitochondrial Oxidative Phosphorylation System Dysfunction in Schizophrenia
Schizophrenia (SCZ) is a severe, chronic mental disorder of unknown etiology and limited therapeutic options. Bioenergetic deficits in the oxidative phosphorylation system (OXPHOS) during early postnatal brain development may underlie disrupted neuronal metabolism and synaptic signaling, contributing to the neurodevelopmental and behavioral disturbances observed in patients. This narrative review summarizes updated evidence linking mitochondrial-OXPHOS dysfunction to SCZ pathophysiology. The novelty lies in the focus on OXPHOS dysfunction at the enzymatic/functional level, rather than on genetic, transcriptional, or oxidative parameters. While complex I impairment has long been highlighted and proposed as a peripheral marker of the disease, recent studies also report alterations in other OXPHOS complexes and their precursors. These findings suggest that OXPHOS dysfunction is not isolated to a single enzymatic component but affects broader mitochondrial function, alongside oxidative stress, contributing to disease progression through mechanisms involving apoptosis, accelerated aging, and synaptic deterioration. OXPHOS dysfunction in both central and peripheral tissues further supports its relevance to SCZ. Overall, the literature points to mitochondrial OXPHOS abnormalities as a significant biological feature of SCZ. Whether these alterations are causal factors or consequences of disease processes remains unclear. Understanding OXPHOS dysregulation may open new avenues for targeted therapies.
- Open Access
- 14 January 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-14
Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia
Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology and cognitive deficits. The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. There is not much research in clinical trials regarding mGluR2/3 PAMs. However, several lines of evidence from animal models have indicated the efficiency of mGluR2/3 PAMs. In this review, focusing on in vivo animal studies, we will specifically discuss the utilization of SZ animal models and the various methods employed to assess animal behaviour before summarising the evidence obtained to date in the field of mGluR2/3 PAMs. By doing so, we aim to deepen our understanding of the underlying mechanisms and the potential efficiency of mGluR2/3 PAMs in treating SZ. Overall, mGluR2/3 PAMs have demonstrated efficiency in attenuating SZ-like behavioural and molecular deficits in animal models and could be useful for the early management of the disorder or to treat specific subsets of patients.
- 14 January 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-14
Open AccessEffectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia
Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology and cognitive deficits. The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. There is not much research in clinical trials regarding mGluR2/3 PAMs. However, several lines of evidence from animal models have indicated the efficiency of mGluR2/3 PAMs. In this review, focusing on in vivo animal studies, we will specifically discuss the utilization of SZ animal models and the various methods employed to assess animal behaviour before summarising the evidence obtained to date in the field of mGluR2/3 PAMs. By doing so, we aim to deepen our understanding of the underlying mechanisms and the potential efficiency of mGluR2/3 PAMs in treating SZ. Overall, mGluR2/3 PAMs have demonstrated efficiency in attenuating SZ-like behavioural and molecular deficits in animal models and could be useful for the early management of the disorder or to treat specific subsets of patients.
- Open Access
- 1 February 2024
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 131, 110955
Effects of the PAM of mGluR2, JNJ-46356479, on brain apoptotic protein levels in a mouse model of schizophrenia
- 1 February 2024
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 131, 110955
Open AccessEffects of the PAM of mGluR2, JNJ-46356479, on brain apoptotic protein levels in a mouse model of schizophrenia
- Open Access
- 20 July 2023
- Published by Springer Nature in Research Square
Association of astrocyte-specific gene expression in the dorsolateral prefrontal cortex with treatment-resistant schizophrenia
Treatment-resistant schizophrenia (TRS) is defined as the absence of symptomatic response to two different adequately administered antipsychotic drugs other than clozapine, which is the most effective drug in these patients. Gene expression profiling studies could be a valuable tool in identifying the specific genes and pathways involved in the mechanism of action of clozapine, leading to a better understanding of the molecular biology underlying TRS. We analyzed gene co-expression modules (clusters of genes with highly correlated expression) in the dorsolateral prefrontal cortex (DLPFC) of postmortem brains from patients with schizophrenia and healthy controls. We aimed to identify the co-expressed modules that reflect the genetic differences between clozapine-treated and non-clozapine-treated patients with schizophrenia as a proxy of TRS. Gene expression of DLPFC samples from 26 subjects with schizophrenia (13 clozapine treated and 13 non-clozapine treated) were analyzed using Clariom S Human Array. Raw gene expression data from 37 healthy controls was downloaded from the GSE92538 datasets. Weighted gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its association with clozapine treatment using a test for interaction. As a result of our analysis of the gene co-expression architecture in the DLPFC, among the 13 modules identified, one module (green) was significantly associated with clozapine treatment. This module was significantly enriched in astrocyte markers and genes involved in the polygenic architecture of TRS. This finding provides cell type-specific associations that could help in the interpretation of the neurobiological basis of TRS. A better understanding of the specific DLPFC cell types involved in TRS will contribute to the study of potential pathways and ultimately help improve psychiatric classification tools in personalized medicine.
- 20 July 2023
- Published by Springer Nature in Research Square
Open AccessAssociation of astrocyte-specific gene expression in the dorsolateral prefrontal cortex with treatment-resistant schizophrenia
Treatment-resistant schizophrenia (TRS) is defined as the absence of symptomatic response to two different adequately administered antipsychotic drugs other than clozapine, which is the most effective drug in these patients. Gene expression profiling studies could be a valuable tool in identifying the specific genes and pathways involved in the mechanism of action of clozapine, leading to a better understanding of the molecular biology underlying TRS. We analyzed gene co-expression modules (clusters of genes with highly correlated expression) in the dorsolateral prefrontal cortex (DLPFC) of postmortem brains from patients with schizophrenia and healthy controls. We aimed to identify the co-expressed modules that reflect the genetic differences between clozapine-treated and non-clozapine-treated patients with schizophrenia as a proxy of TRS. Gene expression of DLPFC samples from 26 subjects with schizophrenia (13 clozapine treated and 13 non-clozapine treated) were analyzed using Clariom S Human Array. Raw gene expression data from 37 healthy controls was downloaded from the GSE92538 datasets. Weighted gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its association with clozapine treatment using a test for interaction. As a result of our analysis of the gene co-expression architecture in the DLPFC, among the 13 modules identified, one module (green) was significantly associated with clozapine treatment. This module was significantly enriched in astrocyte markers and genes involved in the polygenic architecture of TRS. This finding provides cell type-specific associations that could help in the interpretation of the neurobiological basis of TRS. A better understanding of the specific DLPFC cell types involved in TRS will contribute to the study of potential pathways and ultimately help improve psychiatric classification tools in personalized medicine.